

Corvus Pharmaceuticals, Inc.
863 Mitten Road, Suite 102
Burlingame, California 94010

March 17, 2020

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Attention: Courtney Lindsay

Re: Corvus Pharmaceuticals, Inc.
Registration Statement on Form S-3 (Registration No. 333-237040)

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the "**Commission**") of the effective date of the above-referenced Registration Statement on Form S-3 (the "**Registration Statement**") of Corvus Pharmaceuticals, Inc. (the "**Company**"). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on March 19, 2020, or as soon as practicable thereafter.

Thank you for your assistance in this matter.

Very truly yours,

Corvus Pharmaceuticals, Inc.

By: /s/ Leiv Lea
Leiv Lea
Chief Financial Officer

CC: Richard A. Miller, Corvus Pharmaceuticals, Inc.
Alan C. Mendelson, Latham & Watkins LLP
Miles P. Jennings, Latham & Watkins LLP
